2023 Research Partner Update

Achieving Cures Together is on a mission to save lives by restoring microbial health. Our partners at the University of Minnesota Microbiota Therapeutics Program supply microbiota transplant therapeutics to academic partners around the country, working to alleviate suffering and extend the quality of life of patients. Hear directly from our research partners the impact being made in across the health spectrum.

Speaker Videos

Rima Rachid, M.D., Boston Children’s Hospital & Harvard Medical School
Food Allergies
“In our clinical trial there was a 60% efficacy response of reduced reactivity to peanut protein just from one Fecal Microbiota Transplant. It takes about 6 months of oral immunotherapy to reach that level of peanut tolerance.”

Byron Vaughn, M.D., M.S., University of Minnesota
Ulcerative Colitis & Crohn’s Disease
“Ulcerative Colitis patients on Intestinal Microbiota Transplant capsules had a reduction in their symptoms. Patients who received placebo were then given a chance to have the active capsules and when they were on the active capsules, their symptoms got better too.”

Armin Rashidi, M.D., Ph. D., Fred Hutchison Cancer Center
Complications with Acute Leukemia & Stem Cell Transplantation
“The patients I take care of, and try to improve their outcomes, through microbiome therapies are arguably among the most fragile and most immunocompromised patients in medicine.”

Daphne Moutsoglou, M.D., Ph. D., University of Minnesota
Ulcerative Colitis
“We found that Microbiota Transplant Therapy induced significant engraftment in patients with Ulcerative Colitis, and also reduced partial Mayo scores [a scale to rate Ulcerative Colitis disease activity] without any antibiotic preconditioning.”

James Adams, Ph. D. & Rosa Krajmalnik-Brown, Ph. D., Arizona State University
Autism
“We found that the treatment was very safe, actually safer than placebo, that the treatment group had fewer bad days of symptoms than the placebo group. We found it was very effective that 10 weeks of treatment led to a medium improvement in [Autism] symptoms, and an extra 8 weeks of treatment led to even more improvement in symptoms, and the GI symptoms improved substantially as well. We’re now working on planning to optimize dosing for that study for treatment in our next study.”